Frankfurt
30.01.26 | 08:55
5,000 Euro
-1,96 % -0,100
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,050 | 5,300 | 12:27 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.01. | Rodman & Renshaw initiates coverage on Ascentage Pharma stock with Buy rating | 3 | Investing.com | ||
| 07.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.01. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 | 263 | GlobeNewswire (Europe) | Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the... ► Artikel lesen | |
| 31.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.12.25 | ASCENTAGE-B (06855): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | ASCENTAGE-B (06855): (1) CHANGE IN COMPOSITION OF NOMINATION COMMITTEE; (2) APPOINTMENT OF LEAD INDEPENDENT NON-EXECUTIVE DIRECTOR; (3) ESTABLISHMENT ... | 2 | HKEx | ||
| 17.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% | 2 | GlobeNewswire (USA) | ||
| 09.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment | 1 | GlobeNewswire (USA) | ||
| 08.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances | 1 | GlobeNewswire (USA) | ||
| 06.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting | 96 | GlobeNewswire (Europe) | Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.12.25 | Ascentage Gets Regulatory Clearance In The US And Europe To Conduct POLARIS-1 Trial | 2 | RTTNews | ||
| 05.12.25 | Ascentage Pharma To Launch Global Phase III Study Of Olverembatinib In Ph+ ALL | 290 | AFX News | BEIJING (dpa-AFX) - Ascentage Pharma Group International (AAPG, 6855.HK) announced that it received clearance from both the US Food and Drug Administration (FDA) and the European Medicines Agency... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA | 131 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company... ► Artikel lesen | |
| 05.12.25 | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA ANNOUNCES GLOBAL REGISTRATIONAL PHASE III STUDY OF OLVEREMBATINIB IN FIRST-LINE TREATMENT ... | 3 | HKEx | ||
| 01.12.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 | 1 | GlobeNewswire (USA) | ||
| 28.11.25 | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Qiagen: Das ist gewagt! | Dass die sonst zu den ruhigen DAX-Aktien gehörende Qiagen auf einmal in kurzer Zeit einen Kurssprung von in der Spitze 21 Prozent hinlegt, zieht Aufmerksamkeit auf sich. Aber könnte man der Aktie neben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | -0,12 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,03 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| AVIDITY BIOSCIENCES | 72,58 | +0,03 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARVINAS | 13,380 | 0,00 % | Arvinas Inc.: Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders | - ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease - - ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure in subjects... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 5,000 Euro und damit -1,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.